Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
about
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.An analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation.Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation.The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing.HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.Intravenous busulfan dose individualization - impact of modeling approach on dose recommendation.Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in children.Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.Development of multiplex PCR method for the analysis of glutathione s-transferase polymorphism.Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
P2860
Q34479575-541BF4A3-27A7-4CEA-8FBC-F1E8F56E4D5EQ36881201-8FA2AA79-8E72-4A7A-8D1E-1EDD1B87CF8EQ37788219-A9551878-7408-4B35-A7D6-087F08F1E04EQ38060264-E9904697-29E5-4874-8895-75B6DE49C5EAQ38104743-FDCB52F0-A01C-4EA3-A41D-E7F042C9FA59Q38372455-1CB141E6-06FB-439D-8942-EED1412D4A70Q40897000-5A6777C3-C07F-4EB5-91BE-DDFD09A603D1Q41911583-AECBDB87-9944-4B54-9251-4A31380A44FAQ43248045-B26FF0A8-A78E-4462-861E-75AA798AC638Q45936278-3FE1B26A-AB28-4C16-9581-0CF954BAE043Q46091045-E4551243-D133-4D5D-8281-FB18EA0BDD27Q46138906-2162C954-A961-4B76-9A10-7C790AA2BEDCQ47144269-5E728D28-B76E-4D11-B4D8-5AB22733E202Q47173685-C54034F3-5D26-497B-98C2-1FAD34DE80DCQ48254230-2F640018-FD41-4AB0-AD71-4656B2428571Q48333770-0419CC0E-4777-4B87-8EBF-FB6729E5C895Q50717808-8CF03B4A-9E28-4373-BE4C-F43AE13CF79CQ51008175-5440B735-EBCC-4B95-8479-8ADB7FCE71E8Q52552920-DF3A5E2C-074D-4AC3-8C93-4CA4D8312381Q52613271-231FF2AB-2EFB-42C3-B8BC-C8EEA4184E4EQ53399897-8FCA73FB-8FB6-48E2-8BFC-202157347C80Q58789022-CA5A0E16-5792-4D9E-B93F-5BB930FD975E
P2860
Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Once-daily intravenous busulfa ...... eic stem cell transplantation.
@en
Once-daily intravenous busulfa ...... eic stem cell transplantation.
@nl
type
label
Once-daily intravenous busulfa ...... eic stem cell transplantation.
@en
Once-daily intravenous busulfa ...... eic stem cell transplantation.
@nl
prefLabel
Once-daily intravenous busulfa ...... eic stem cell transplantation.
@en
Once-daily intravenous busulfa ...... eic stem cell transplantation.
@nl
P2093
P1476
Once-daily intravenous busulfa ...... eic stem cell transplantation.
@en
P2093
Carin M A Rademaker
Charlotte van Kesteren
Cuno S P M Uiterwaal
Imke H Bartelink
J den Hartigh
Jaap J Boelens
Juliette Zwaveling
Marc Bierings
Martine F Raphael
Robbert G M Bredius
P356
10.1016/J.BBMT.2007.09.015
P577
2008-01-01T00:00:00Z